Drotrecogin Alfa in Patients With Burns and Soft Tissue Injury

摘要

In 2004, guidelines on the management of severe sepsis and septic shock known as the "Surviving Sepsis Campaign" were published after an expert panel representing critical care and infectious disease experts from 11 international organizations agreed on the guidelines. From these controversial guidelines, drotrecogin alfa (DrotAA) or recombinant human activated protein C, was advocated for all septic patients who did not have obvious contraindications to the drug. In the subset analysis of the original study on the efficacy of DrotAA in sepsis, there was a survival benefit found for septic surgical patients with high Acute Physiology and Chronic Health Evaluation Scores (APACHE) treated with DrotAA. Exclusion criteria for the study included patients with burns. There has been very little published on the use of DrotAA in burn patients. The aim of this case series report is to summarize our experience with the use of DrotAA in soft tissue injury patients.